Evaluation of antibody-chemokine fusion proteins for tumor-targeting applications

Experimental Biology and Medicine

Volumn 239, Issue 7, 2014, Pages 842-852

  Hess, Christian ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

antibody chemokine fusion protein; armed antibody; chemokine; Immunochemokine; oncofetal fibronectin; vascular targeting

Indexed keywords

FIBRONECTIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYBRID PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; SECONDARY LYMPHOID TISSUE CHEMOKINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHEMOTAXIS ASSAY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL PERMEATION CHROMATOGRAPHY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; ION EXCHANGE CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR CLONING; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PROTEIN PURIFICATION; SURFACE PLASMON RESONANCE; WESTERN BLOTTING;

EID: 84904876346     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370214536667     Document Type: Article

References (76)

1. Aggarwal S.What's fueling the biotech engine - 2010 to 2011.Nat Biotechnol. 2011;29:1083-9.
2. Sievers EL,Senter PD.Antibody-drug conjugates in cancer therapy.Annu Rev Med. 2012;64:15-29.
3. Teicher BA,Chari RV.Antibody conjugate therapeutics: challenges and potential.Clin Cancer Res. 2011;17:6389-97.
4. Pasche N,Neri D.Immunocytokines: a novel class of potent armed antibodies.Drug Discov Today. 2012;17:583-90.
5. Kontermann RE.Antibody-cytokine fusion proteins.Arch Biochem Biophys. 2012;526:194-205.
6. Govindan SV,Griffiths GL,Hansen HJ,Horak ID,Goldenberg DM.Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies.Technol Cancer Res Treat. 2005;4:375-91.
7. Steiner M,Neri D.Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends.Clin Cancer Res. 2011;17:6406-16.
8. Guo JQ,Chen L,Ai HW,Jing JN,Zhou JY,Zhang CY,You SY.A novel fusion protein of IP10-scFv retains antibody specificity and chemokine function.Biochem Biophys Res Commun. 2004;320:506-13.
9. Challita-Eid PM,Abboud CN,Morrison SL,Penichet ML,Rosell KE,Poles T,Hilchey SP,Planelles V,Rosenblatt JD.A RANTES-antibody fusion protein retains antigen specificity and chemokine function.J Immunol. 1998;161:3729-36.
10. Li J,Hu P,Khawli LA,Epstein AL.LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors.J Immunother. 2003;26:320-31.
11. Yoshie O,Imai T,Nomiyama H.Chemokines in immunity.Adv Immunol. 2001;78:57-110.
12. Neel NF,Barzik M,Raman D,Sobolik-Delmaire T,Sai J,Ham AJ,Mernaugh RL,Gertler FB,Richmond A.VASP is a CXCR2-interacting protein that regulates CXCR2-mediated polarization and chemotaxis.J Cell Sci. 2009;122:1882-94.
13. Raman D,Neel NF,Sai J,Mernaugh RL,Ham AJ,Richmond AJ.Characterization of chemokine receptor CXCR2 interacting proteins using a proteomics approach to define the CXCR2 "chemosynapse".Methods Enzymol. 2009;460:315-30.
14. Raman D,Sai J,Neel NF,Chew CS,Richmond A.LIM and SH3 protein-1 modulates CXCR2-mediated cell migration.PLoS One. 2010;5:e10050-e10050.
15. Allen SJ,Crown SE,Handel TM.Chemokine: receptor structure, interactions, and antagonism.Annu Rev Immunol. 2007;25:787-820.
16. Van Damme J,Struyf S,Wuyts A,Van Coillie E,Menten P,Schols D,Sozzani S,De Meester I,Proost P.The role of CD26/DPP IV in chemokine processing.Chem Immunol. 1999;72:42-56.
17. Van Damme J,Struyf S,Opdenakker G.Chemokine-protease interactions in cancer.Semin Cancer Biol. 2004;14:201-8.
18. Overall CM,McQuibban GA,Clark-Lewis I.Discovery of chemokine substrates for matrix metalloproteinases by exosite scanning: a new tool for degradomics.Biol Chem. 2002;383:1059-66.
19. Opdenakker G,Van Damme J.Chemokines and proteinases in autoimmune diseases and cancer.Verh K Acad Geneeskd Belg. 2002;64:105-36.
20. Overall CM,Kleifeld O.Towards third generation matrix metalloproteinase inhibitors for cancer therapy.Br J Cancer. 2006;94:941-6.
21. Overall CM,Kleifeld O.Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.Nat Rev Cancer. 2006;6:227-39.
22. McQuibban GA,Gong JH,Wong JP,Wallace JL,Clark-Lewis I,Overall CM.Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo.Blood. 2002;100:1160-7.
23. McQuibban GA,Butler GS,Gong JH,Bendall L,Power C,Clark-Lewis I,Overall CM.Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1.J Biol Chem. 2001;276:43503-8.
24. Parks WC,Wilson CL,Lopez-Boado YS.Matrix metalloproteinases as modulators of inflammation and innate immunity.Nat Rev Immunol. 2004;4:617-29.
25. Sharma S,Stolina M,Luo J,Strieter RM,Burdick M,Zhu LX,Batra RK,Dubinett SM.Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo.J Immunol. 2000;164:4558-63.
26. Braun SE,Chen K,Foster RG,Kim CH,Hromas R,Kaplan MH,Broxmeyer HE,Cornetta K.The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells.J Immunol. 2000;164:4025-31.
27. Hillinger S,Yang SC,Zhu L,Huang M,Duckett R,Atianzar K,Batra RK,Strieter RM,Dubinett SM,Sharma S.EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model.J Immunol. 2003;171:6457-65.
28. Soto H,Wang W,Strieter RM,Copeland NG,Gilbert DJ,Jenkins NA,Hedrick J,Zlotnik A.The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3.Proc Natl Acad Sci USA. 1998;95:8205-10.
29. Sharma S,Yang SC,Hillinger S,Zhu LX,Huang M,Batra RK,Lin JF,Burdick MD,Strieter RM,Dubinett SM.SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10.Mol Cancer. 2003;2:22-22.
30. Dubinett SM,Lee JM,Sharma S,Mule JJ.Chemokines: can effector cells be redirected to the site of the tumor?.Cancer J. 2010;16:325-35.
31. Hensbergen PJ,Wijnands PG,Schreurs MW,Scheper RJ,Willemze R,Tensen CP.The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.J Immunother. 2005;28:343-51.
32. Inoue H,Iga M,Xin M,Asahi S,Nakamura T,Kurita R,Nakayama M,Nakazaki Y,Takayama K,Nakanishi Y,Tani K.TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model.Cancer Immunol Immunother. 2008;57:1399-411.
33. Fushimi T,Kojima A,Moore MA,Crystal RG.Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth.J Clin Invest. 2000;105:1383-93.
34. Folkman J.Fundamental concepts of the angiogenic process.Curr Mol Med. 2003;3:643-51.
35. Mohit E,Rafati S.Chemokine-based immunotherapy: delivery systems and combination therapies.Immunotherapy. 2012;4:807-40.
36. Strieter RM,Belperio JA,Phillips RJ,Keane MP.CXC chemokines in angiogenesis of cancer.Semin Cancer Biol. 2004;14:195-200.
37. Strieter RM,Burdick MD,Mestas J,Gomperts B,Keane MP,Belperio JA.Cancer CXC chemokine networks and tumour angiogenesis.Eur J Cancer. 2006;42:768-78.
38. Addison CL,Arenberg DA,Morris SB,Xue YY,Burdick MD,Mulligan MS,Iannettoni MD,Strieter RM.The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis.Hum Gene Ther. 2000;11:247-61.
39. Strieter RM,Kunkel SL,Arenberg DA,Burdick MD,Polverini PJ.Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis.Biochem Biophys Res Commun. 1995;210:51-7.
40. Burdick MD,Murray LA,Keane MP,Xue YY,Zisman DA,Belperio JA,Strieter RM.CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling.Am J Respir Crit Care Med. 2005;171:261-8.
41. Schwager K,Bootz F,Imesch P,Kaspar M,Trachsel E,Neri D.The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model.Hum Reprod. 2011;26:2344-52.
42. Schwager K,Kaspar M,Bootz F,Marcolongo R,Paresce E,Neri D,Trachsel E.Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.Arthritis Res Ther. 2009;11:R142-R142.
43. Rosenblatt JD,Shin SU,Nechustan H,Yi KH,Tolba K.Potential role of chemokines in immune therapy of cancer.Isr Med Assoc J. 2002;4:1054-9.
44. Challita-Eid PM,Abboud CN,Morrison SL,Penichet ML,Rosell KE,Poles T,Hilchey SP,Planelles V,Rosenblatt JD.A RANTES-antibody fusion protein retains antigen specificity and chemokine function.J Immunol. 1998;161:3729-36.
45. Hornick JL,Sharifi J,Khawli LA,Hu P,Biela BH,Mizokami MM,Yun A,Taylor CR,Epstein AL.A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors.Cancer Biother Radiopharm. 1998;13:255-68.
46. Guo JQ,Li QM,Zhou JY,Zhang GP,Yang YY,Xing GX,Zhao D,You SY,Zhang CY.Efficient recovery of the functional IP10-scFv fusion protein from inclusion bodies with an on-column refolding system.Protein Expr Purif. 2006;45:168-74.
47. Villa A,Trachsel E,Kaspar M,Schliemann C,Sommavilla R,Rybak JN,Rosli C,Borsi L,Neri D.A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.Int J Cancer. 2008;122:2405-13.
48. Rybak JN,Roesli C,Kaspar M,Villa A,Neri D.The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases.Cancer Res. 2007;67:10948-57.
49. Moschetta M,Pretto F,Berndt A,Galler K,Richter P,Bassi A,Oliva P,Micotti E,Valbusa G,Schwager K,Kaspar M,Trachsel E,Kosmehl H,Bani MR,Neri D,Giavazzi R.Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts.Cancer Res. 2012;72:1814-24.
50. Sommavilla R,Pasche N,Trachsel E,Giovannoni L,Roesli C,Villa A,Neri D,Kaspar M.Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.Protein Eng Des Sel. 2010;23:653-61.
51. Villa A,Lovato V,Bujak E,Wulhfard S,Pasche N,Neri D.A novel synthetic naive human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin.MAbs. 2011;3:264-72.
52. Villa A,Trachsel E,Kaspar M,Schliemann C,Sommavilla R,Rybak JN,Rosli C,Borsi L,Neri D.A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.Int J Cancer. 2008;122:2405-13.
53. Wang P,Yang X,Xu W,Li K,Chu Y,Xiong S.Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: a strategy for chemokine-based multi-target-directed cancer therapy.Cancer Immunol Immunother. 2010;59:1715-26.
54. Pasche N,Woytschak J,Wulhfard S,Villa A,Frey K,Neri D.Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7.J Biotechnol. 2011;154:84-92.
55. Frey K,Zivanovic A,Schwager K,Neri D.Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.Integr Biol. 2011;3:468-78.
56. Wulhfard S. Transient recombinant protein expression in mammalian cells: the role of mRNA level and stability, 2009. Doctoral dissertation, doi:10.5075/epfl-thesis-4393.
57. Mortier A,Van Damme J,Proost P.Overview of the mechanisms regulating chemokine activity and availability.Immunol Lett. 2012;145:2-9.
58. Mortier A,Gouwy M,Van Damme J,Proost P.Effect of posttranslational processing on the in vitro and in vivo activity of chemokines.Exp Cell Res. 2011;317:642-54.
59. Menten P,Wuyts A,Van Damme J.Purification, identification, and synthesis of chemokines.Methods Mol Biol. 2004;249:47-64.
60. Proudfoot AE,Borlat F.Purification of recombinant chemokines from E.coli. Methods Mol Biol. 2000;138:75-87.
61. Melkko S,Halin C,Borsi L,Zardi L,Neri D.An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance.Int J Radiat Oncol Biol Phys. 2002;54:1485-90.
62. Niesner U,Halin C,Lozzi L,Gunthert M,Neri P,Wunderli-Allenspach H,Zardi L,Neri D.Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides.Bioconjug Chem. 2002;13:729-36.
63. Hemmerle T,Wulhfard S,Neri D.A critical evaluation of the tumor-targeting properties of bispecific antibodies based on quantitative biodistribution data.Protein Eng Des Sel. 2012;25:851-4.
64. Mantovani A,Locati M,Vecchi A,Sozzani S,Allavena P.Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines.Trends Immunol. 2001;22:328-36.
65. Mantovani A,Bonecchi R,Locati M.Tuning inflammation and immunity by chemokine sequestration: decoys and more.Nat Rev Immunol. 2006;6:907-18.
66. Borsi L,Balza E,Bestagno M,Castellani P,Carnemolla B,Biro A,Leprini A,Sepulveda J,Burrone O,Neri D,Zardi L.Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin.Int J Cancer. 2002;102:75-85.
67. Hemmerle T,Neri D.The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.Int J Cancer. 2013;134:467-77.
68. Khawli LA,Hu P,Epstein AL.Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.Handb Exp Pharmacol. 2008;181:291-328.
69. Mizokami MM,Hu P,Khawli LA,Li J,Epstein AL.Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies.Hybrid Hybridomics. 2003;22:197-207.
70. Li J,Hu P,Khawli LA,Epstein AL.Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.Cancer Res. 2003;63:8384-92.
71. Lechner MG,Russell SM,Bass RS,Epstein AL.Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.Immunotherapy. 2011;3:1317-40.
72. Rybak JN,Roesli C,Kaspar M,Villa A,Neri D.The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases.Cancer Res. 2007;67:10948-57.
73. Schliemann C,Wiedmer A,Pedretti M,Szczepanowski M,Klapper W,Neri D.Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma.Leuk Res. 2009;33:1718-22.
74. Gutbrodt KL,Schliemann C,Giovannoni L,Frey K,Pabst T,Klapper W,Berdel WE,Neri D.Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia.Sci Transl Med. 2013;5:201ra118-201ra118.
75. Halin C,Niesner U,Villani ME,Zardi L,Neri D.Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins.Int J Cancer. 2002;102:109-16.
76. Yang J,Richmond A.The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan.Mol Ther. 2004;9:846-55.